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SUMMARY
What is known and objective: Antiretroviral treatment (ART) is
hampered by complicated regimens, high pill burden, drug–
drug interactions, and frequent short- and long-term adverse
effects, leading to decreased adherence. Over recent years,
considerable effort has been directed at developing regimens
that are less burdening. We undertook a 7-year retrospective
study of the records of 264 HIV-infected subjects enrolled in a
pharmaceutical care programme to document the progress made
and to study the influence of the number of ART pills and doses
on the level of treatment adherence.
Methods: Antiretroviral dispensing records were analysed for
the number of pills and doses administered and the ART
adherence rate estimated.
Results and discussion: In 2005, the patients took a mean of 62
pills daily (CI 95%: 59–66), and 929% of them were on a twice-
a-day (BID) dosage regimen. By 2012, the mean number of pills
was reduced to 41 (CI 95%: 38–44), and only 509% were on a
BID regimen. No statistically significant relation was observed
between number of daily pills and doses and ART adherence
reached by the patients in any of the analyses performed.
What is new and conclusions: There has been a continuous
reduction in the number of pills and doses of antiretrovirals
taken by individual patients over the last 7 years due largely to
the introduction of improved treatments and regimens. More
daily pills or doses was not associated with worse ART
adherence in our pharmaceutical care programme.
WHAT IS KNOWN AND OBJECTIVE
Antiretroviral treatment (ART) aims to improve survival and
quality of life of the patients with HIV infection and reduce
transmission of the infection. These are achieved by maintaining
the CD4+ lymphocytes count within the normal range and
obtaining complete control of viral replication.1
ART has been steadily improving particularly since the intro-
duction of potent combination therapy in 1996. New drugs with
new mechanisms of action, improved potency and activity even
against multidrug-resistant viruses, dosing convenience, and
tolerability have been approved. These newer drugs have
dramatically reduced HIV-associated morbidity and mortality
and have transformed HIV infection from a rapidly lethal
condition into a chronic one.1 However, the success of ART has
been hampered by complicated regimens, high pill burden, drug–
drug interactions, and frequent short- and long-term adverse
effects, leading to decreased adherence to prescribed regimens.
Currently, lack of adherence to ART continues to be one of the
principal factors in therapeutic failure and the development of
viral resistance.2,3
Adherence is the result of a complex process that involves
acceptance of the diagnosis, perception of the need to correctly
carry out the treatment, and motivation to do so. Furthermore,
possession of appropriate skills, ability to overcome any difficul-
ties that appear and maintenance of the level of achievement
reached over time are necessary.4 The development of strategies
for improving ART adherence requires knowledge of the influen-
tial factors and how these factors exert their effects. In general, it is
accepted that motivational and daily-habit-modifying strategies
are the most effective ones.5–7
Several studies have shown that the characteristics of the
antiretroviral regimens may affect ART adherence. These studies
have described a direct association between antiretroviral treat-
ment non-adherence and burden in the number of pills.8,9
Higher adherence levels have been reported in patients on a
once-daily (OD) vs. twice-daily (BID) or three-times-a-day (TID)
regimens.10–13 Due to these findings, a concerted effort has been
made to reduce both pill burden and dosing frequency.14,15 Two
types of improvements are possible. The first is based on
optimizing the presentation of each medication by increasing the
amount of drug contained in each pill or increasing its half life.
The second involved including two or more antiretrovirals into
one pill.
This study aimed to analyse the evolution over time of the
number of ART pills and doses taken by individual patients and
the influence of these factors on the level of treatment adherence
by a group of HIV-infected patients participating in a pharma-
ceutical care programme.
METHODS
A 7-year long retrospective study with data from HIV-infected
patients treated in the Pharmacy Service outpatient unit of the
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University Hospital of Salamanca, Spain was conducted (April
2005–April 2012). Inclusion criteria were as follows: patients with
confirmed HIV infection who had been receiving ART in our
hospital during the entire study period.
Adherence measures
Many scientific studies and consensus documents have recom-
mended the use and combination of at least two adherence
evaluation methods to yield reliable results.1,16 Therapeutic drug
monitoring (TDM) (direct method), antiretrovirals dispensing
records (DR) and simplified medication adherence questionnaire
(SMAQ)17 (indirect methods) are routinely used in our care
practice.
A previous 5-year study of ours showed a correlation between
DR and SMAQ (measurement of self-reported adherence by the
patient) during the study period.18 The current study used the DR
method because it makes possible the quantification of adherence
as a continuous variable. Adherence was calculated, for 6-month
periods beginning from the initiation of the study (April 2005).
The adherence level for each period was obtained from the
number of pills taken during that period divided by the number
of pills prescribed during the same period. Levels that exceeded
100% were rounded down to 100%. Patients who consumed ≥95%
of the medication prescribed were considered ‘adherent
patients’.19
Daily pills and doses
Antiviral treatment was characterized by the number of pills and
doses that the patient needed per day. This number was obtained
from the DR for each patient using 6-month periods beginning at
the onset of the study. This was compared with adherence in these
same periods. For patients who had switched treatment, the
number of pills and doses corresponding to the longest period
within the 6-month period evaluated was used.
The analysis strategies were based on the study of the following
relationships:
1Relationship between the number of daily pills or doses with the
level of adherence. Adherence was used as a continuous variable
and categorized into two levels: ≥95% vs. <95%.
2Relationship between the change in the number of daily pills or
doses with the change in adherence level.
3Relationship between the number of daily pills or doses with
adherence level stratified into four categories at the start and end
of the study (<60%, 60–79%, 80–94%, 95–100%).19 The percentage
of patients in the total population with the same number of pills or
doses was calculated in each case. The cut-off for number of pills
corresponds to the number that optimized sampling sizes: four
and three for the baseline and final situation, respectively. Cut-off
for dose number was one.
Statistical analyses
The chi-square test for independence, also called Pearson’s chi-
square test, was used to study if there was a relationship between
categorical variables. Spearman’s correlation was used to study the
relationship between quantitative or ordinal variables and Bon-
ferroni correction was conducted. The Z test was used for the
comparison of proportions. Furthermore, logistic regression mod-
els were constructed to investigate the association of the number of
pills or doses with the dichotomous outcomes of adherence (<95%
vs. ≥95%). IBM SPSS Statistics for Windows version 20.0.0.220 and
Epidat 3.121 were used for the statistical analyses.
RESULTS
A total of 264 patients who received pharmacological treatment
during the entire study period were included. Baseline demo-
graphic and clinical characteristics of the total study population
are given in Table 1.
Evolution of the number of daily pills and doses during the study
During the 7 years of the study, 3610 records of the number
of pills and the same number of records for doses in the
patients enrolled were obtained. Evolution of the number of
daily pills or doses during the study is shown in Fig. 1(a) and
Table S1.
In addition, the evolution in the number of pills at the beginning
and end of the study based on whether treatment was adminis-
tered in a OD, BID or TID regimen was studied. The results are
shown in Table 2.
The evolution in time of the percentage of the patients who were
using the less complex regimens, that is less than five antiretroviral
pills per day and/or a single dose per day, was also analysed
[Fig. 1(b)].
Relation between pills and doses with adherence
Three different strategies were used to analyse the possible relation
between the number of pills or doses and adherence:
Relation between the number of daily pills or doses with adherence in
each studied period. No significant relation was observed when
adherence was studied as a continuous variable. However, all the
estimated correlations have the expected sign ðq̂\0Þ, indicating a
decrease of adherence when the number of daily pills or doses
increases.
On the other hand, when adherence was categorized into two
levels, no clear pattern was found in the logistic regression analysis
to relate number of daily pills and doses with adherence or non-
adherence.
Relation between the change in number of daily pills and doses with the
change in adherence in each studied period. No statistically significant
relation was found between the change in number of pills and




Mean  SD (range) or n (%)
Age (years) 4058  881
Male 180 (682)
Number of years on ART 535  360
CD4+ counts (cells/mcL)
a 39816  24057
Undetectable plasma viral loada 191 (853)
SD, standard deviation; n, number; ART, antiretroviral treatment.
aThe variable only refers to those patients for whom these clinical data were
available.
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doses in each patient with the change in adherence in the period
studied or in the period immediately follow it.
Relation between number of daily pills and doses with adherence
stratified into four categories at the onset and end of the study. Regard-
ing number of pills, 157 patients showed high pill burden at the
beginning of the study (>4 pills) and 140 patients at the end of it
(>3 pills). It can be observed that: (i) the percentage of adherent
patients was greater than the non-adherent, both globally and by
the number of pills; (ii) the percentage of patients with optimal
adherences was slightly greater in the patients who took fewer
pills; and (iii) there were no statistically significant differences
between the two groups in any of the four adherence sections
(Fig. 2).
No statistically significant differences were observed between
both groups in any of the four adherence sections in relation to
dose (Fig. 3).
The results of analysis at the end of the study established that: (i)
there was no patient group in which adherence was less than 60%,
(ii) the percentage of patients in the ≥95% adherence range
increased considerably (P = 00015), and (iii) number of daily pills
or doses did not affect adherence reached by the patients.
DISCUSSION
Adequate antiretroviral treatment adherence is undoubtedly one
of the fundamental requirements for success.19,22 For this reason,
the study of the different factors that may improve patient
adherence with the pharmacotherapy has led to great interest
within the scientific and health care setting.23,24
The patients included in the study had a mean antiretroviral
treatment time (at the onset of the study) of approximately 5 years.
Globally, the clinical status of the patients was good, with an
approximate mean CD4+ lymphocyte count of 400 and unde-
tectable plasma viral load in 85% of the cases.
Evolution of the number of daily pills and doses during the study
The study was initiated in 2005. As can be seen in Table 2, at that
time, the patients were taking a mean of 62 pills daily, 929% of
(a) (b)
Fig. 1. Mean number of daily pills and doses during the study period (a) and percentage of patients taking less than five pills daily and
that of patients on the OD regimen (b). AR, antiretrovirals; OD, once a day.
Table 2. Number of patients and number of daily pills at the beginning and end of the study, based on type of administration regimen
(OD, BID or TID)
Administration regimen
OD BID TID
Baseline Final Baseline Final Baseline Final
Number of patients 10 129 221 134 7 0
Number of daily pills
Mean (range)
35 (2–5) 28 (1–6) 62 (2–15) 54 (2–10) 81 (4–12) –
OD, once a day; BID, twice a day; TID, three times a day.
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them with a BID regimen. At the end of the study (2012), mean
number of pills that the patients were taking decreased to 41
[Fig. 1(a)] and only 509% of them with a BID regimen. The
reduction observed in the frequency of use of BID regimens was
associated to a considerable increase in the OD regimens. This
latter increased from 41% in the year 2005 to 491% in 2012.
The tendency observed in the reduction of the number of doses
was been observed in the TID regimens too. These went from
29% at the onset of the study to disappearing at the end of it.
As can be seen in Fig. 1(b), it should also be stressed that only
320% of the patients in 2005 were taking less than five pills and
that this amount practically doubled by the end of the study
(604%).
The spectacular increase of simpler regimens in our population
in the period studied can be explained by the marketing of new
formulations, by the low frequency of drug resistance mutations in
our patient population, and a high proportion of patients on their
first treatments. People with first-line regimens are more likely to
receive a reduced number of pills and doses. This may in turn have
accounted for the high rates of adherence recorded in our
population, even at baseline measurement and the prolonged
efficacy of treatment.
Consensus does exist that patients prefer the simpler regimens,
ideally OD, and those with only one pill.25–28
However, no consensus has been found on whether this
reduction in the number of pills and doses objectively leads to
improvement in patient adherence with their antiretroviral
medication.11,12,29
Relation between daily pills and doses with adherence
Based on the existing controversy in the literature on the influence
of the number of pills and doses on adherence to ART, we carried
out this study over a 7-year period. Bearing in mind that the results
obtained often depended on the type of analysis performed, on the
criteria used and even on the statistical analyses chosen, we
considered that it was necessary to analyse the possible influence
from different points of view in order to obtain general conclusions
that attempt to clarify the information existing up to date:
When the relation between number of pills or doses with
adherence was studied, no statistical significance was observed in
any of the periods studied. When the changes in the number of
pills or doses were compared with changes in adherence, no
statistically significant relation between them was observed.
(a) (b)
Fig. 2. Percentage of patients, at each adher-
ence level, based on number of daily pills, at
the beginning (a) and end of the study (b).
Note: patients for whom baseline and final
data of number of daily pills and adherence
were available (n = 229 and n = 246, respec-
tively).
(a) (b)
Fig. 3. Percentage of patients, at each adherence level, based on number of daily doses, at the beginning (a) and end of the study (b). Note:
patients for whom baseline and final data of number of daily doses and adherence were available (n = 230 and n = 246, respectively).
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Finally, no relation was observed between number of pills or
doses and whether the patient was ART adherent or non-adherent.
For the number of pills, it appears that the number of times the
patient takes the pills per day is more important than the number
of pills as more frequent dosing may interfere with the patient’s
daily activities. Our results on number of pills and doses are
similar to those reported in a recent meta-analysis.30
Finally, we would like to think that the good results observed
reflect positively on the continuous 7-year pharmaceutical care
programme. Thus, the patients were instructed on the importance
of taking their antiretroviral medication correctly and about not
forgetting to take it. In this sense, it is possible that these results
cannot be extrapolated to care centres in which this type of follow-
up does not exist or to settings in which the antiretroviral drugs
are not dispensed centrally in hospital pharmacies. However, our
study design does not allow the impact of our programme to be
independently estimated.
Many factors influence ART adherence, including demographic
factors, clinical management and drug adverse effects and again
these could not be assessed independently in our study.
Currently, due to important and growing economic restrictions
on health care costs, there is a tendency to ‘break up’ fixed-dose
combinations of antiretrovirals31 to enable the use of antiretroviral
drugs individually, especially with less expensive generic drugs.32
The savings can be considerable. Our study results suggest that
this strategy is unlikely to affect patient adherence, at least in our
setting.
WHAT IS NEW AND CONCLUSION
The number of daily pills during the 7-year study period decreased
from about six to four. An increase was observed in the frequency
of OD regimens instead of BID regimens. No relationship was
found between number of daily pills or doses of the antiretroviral
medication and adherence in our pharmaceutical care programme.
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